Cargando…
Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
BACKGROUND/AIMS: The aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymphoma. METHODS: A retro...
Autores principales: | Lim, Kyu-Hyoung, Yoon, Ho-Il, Kang, Young Ae, Lee, Keun-Wook, Kim, Jee Hyun, Bang, Soo-Mee, Lee, Jae Ho, Lee, Choon-Taek, Lee, Jong Seok |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829422/ https://www.ncbi.nlm.nih.gov/pubmed/20195409 http://dx.doi.org/10.3904/kjim.2010.25.1.86 |
Ejemplares similares
-
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
por: Candelaria, Myrna, et al.
Publicado: (2021) -
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
por: Lee, Eun Ju, et al.
Publicado: (2014) -
Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
por: Go, Se‐Il, et al.
Publicado: (2016) -
Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
por: Song, Guoqi, et al.
Publicado: (2016) -
Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
por: van Keep, Marjolijn, et al.
Publicado: (2016)